Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), a pioneering life sciences technology firm that offers critical automation solutions to streamline the manufacturing and expedite the safe release of healthcare products, today announced its participation in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, in New York City.

Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, will represent the Company during a 35-minute question-and-answer session with the host analyst, scheduled to begin at 7:00 a.m. Eastern Time. 

Rapid Micro Biosystems is at the forefront of life sciences technology, offering essential automation solutions that facilitate the efficient production and prompt, safe release of critical healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship product, the Growth Direct™ system, revolutionizes outdated manual microbial quality control (MQC) testing workflows, which are crucial in large-scale pharmaceutical manufacturing operations globally. By bringing MQC automation directly to the manufacturing floor, the Growth Direct system provides faster results, enhanced accuracy, improved operational efficiency, and superior compliance with data integrity regulations, enabling quicker decision-making processes.

Headquartered in Lexington, Massachusetts, Rapid Micro Biosystems operates a U.S. manufacturing facility in Lowell, Massachusetts, and maintains global offices in Switzerland, Germany, and the Netherlands.